Last reviewed 2026-05-22 · How we verify

Beta-blockers withdrawal

Beta-blockers withdrawal is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently FDA-approved.

Beta-blockers withdrawal can be managed through down-titration, as seen in clinical trials for heart failure patients in remission. This approach involves gradually reducing the dosage of beta-blockers to minimize potential withdrawal effects, as studied in clinical trials such as NCT07513883.

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• N-of-1 Trial to Promote Beta-Blocker Titration in Heart Failure (NA)
• De-Adoption of Beta-Blockers in Patients With Stable Ischemic Heart Disease (PHASE4)
• N-of-1 for Beta-Blockers in Cardiac Amyloidosis (PHASE4)
• A Preliminary Study for INFORMED (PHASE4)
• WithDRawal Impact Of Postoperative Beta-Blocker (NA)
• Mindfulness Therapy for Chronic Migraine (PHASE4)
• Propranolol for Sleep Apnea Therapy (PHASE2)
• Evaluation of Early CRRT InTerventions in Patients With ECMO(ELITE) (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Beta-blockers withdrawal CI brief — competitive landscape report
• Beta-blockers withdrawal updates RSS · CI watch RSS
• Assistance Publique - Hôpitaux de Paris portfolio CI

Frequently asked questions about Beta-blockers withdrawal

Related

• Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing